Compare Intel Corp (INTC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs GeneDx Holdings Corp — how do they compare? Intel Corp trades at $108.56 (market cap $566.04B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Intel Corp is far larger — about 280.2× GeneDx Holdings Corp's market cap, and Intel Corp pays a 2.24% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and GeneDx Holdings Corp for 19 Days on average.
| INTC | WGS | |
|---|---|---|
Market Cap | $566.04B | $2.02B |
Volume | 118,475,837 | 734,640 |
Sector | Technology | Health |
52-Week High | $140.94 | $167.51 |
52-Week Low | $33.62 | $34.51 |
Typical Hold Time | 116 Days | 19 Days |
Enterprise Value | $586.85B | $2.05B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $113.12, up 0.55% on the day, with a bullish technical signal supported by moving averages. Recent earnings beats and a 222% stock surge in 2026 reflect strong AI momentum and foundry growth, though negative net income and high valuation ratios signal caution. The company's cash flow improved in 2025, but competitive pressures and margin challenges persist.
The outlook hinges on Intel's foundry turnaround gaining traction, with revenue growth and external customer adoption as key catalysts. Risks include intense competition, high debt, and execution uncertainty. Analyst consensus is mixed, with a hold rating dominant, suggesting cautious optimism amid fundamental headwinds.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
